Mid Cap Biotechnology Analyst Joseph and European Pharmaceuticals Analyst Gordon, along with Dr. Hogarth, Prof of Medicine in Pulmonary & Critical Care at the University of Chicago discuss the advances in the AATD therapeutic landscape (relevant companies BEAM WVE) on an Analyst/Industry conference call to be held on April 28 at 10 am.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics today
- Beam Therapeutics’ BEAM-302: Promising Clinical Data and Market Potential Drive Buy Rating
- Beam Therapeutics presents additional data for BEAM-302 in AATD
- Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today
- Biotech stocks slide as Marks resignation seen being negative for sector